45 results on '"Grimm, Jimm"'
Search Results
2. A prospective evaluation of hippocampal radiation dose volume effects and memory deficits following cranial irradiation
- Author
-
Ma, Ting Martin, Grimm, Jimm, McIntyre, Riley, Anderson-Keightly, Heather, Kleinberg, Lawrence R., Hales, Russell K., Moore, Joseph, Vannorsdall, Tracy, and Redmond, Kristin J.
- Published
- 2017
- Full Text
- View/download PDF
3. Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models
- Author
-
Liu, Feng, Tai, An, Lee, Percy, Biswas, Tithi, Ding, George X., El Naqa, Isaam, Grimm, Jimm, Jackson, Andrew, Kong, Feng-Ming (Spring), LaCouture, Tamara, Loo, Billy, Jr., Miften, Moyed, Solberg, Timothy, and Li, X. Allen
- Published
- 2017
- Full Text
- View/download PDF
4. Initial Data Pooling for Radiation Dose-Volume Tolerance for Carotid Artery Blowout and Other Bleeding Events in Hypofractionated Head and Neck Retreatments.
- Author
-
Grimm, Jimm, Vargo, John A., Mavroidis, Panayiotis, Moiseenko, Vitali, Emami, Bahman, Jain, Sheena, Caudell, Jimmy J., Clump, David A., Ling, Diane C., Das, Shiva, Moros, Eduardo G., Vinogradskiy, Yevgeniy, Xue, Jinyu, and Heron, Dwight E.
- Subjects
- *
RADIATION tolerance , *CAROTID artery , *NECK , *RADIOTHERAPY , *SPINAL cord - Abstract
Purpose: Dose-volume data for injury to carotid artery and other major vessels in stereotactic body radiation therapy (SBRT)/SABR head and neck reirradiation were reviewed, modeled, and summarized.Methods and Materials: A PubMed search of the English-language literature (stereotactic and carotid and radiation) in April 2018 found 238 major vessel maximum point doses in 6 articles that were pooled for logistic modeling. Two subsequent studies with dose-volume major vessel data were modeled separately for comparison. Attempts were made to separate carotid blowout syndrome from other bleeding events (BE) in the analysis, but we acknowledge that all except 1 data set has some element of BE interspersed.Results: Prior radiation therapy (RT) dose was not uniformly reported per patient in the studies included, but a course on the order of conventionally fractionated 70 Gy was considered for the purposes of the analysis (with an approximately ≥6-month estimated interval between prior and subsequent treatment in most cases). Factors likely associated with reduced risk of BE include nonconsecutive daily treatment, lower extent of circumferential tumor involvement around the vessel, and no surgical manipulation before or after SBRT.Conclusions: Initial data pooling for reirradiation involving the carotid artery resulted in 3 preliminary models compared in this Hypofractionated Treatment Effects in the Clinic (HyTEC) report. More recent experiences with alternating fractionation schedules and additional risk-reduction strategies are also presented. Complications data for the most critical structures such as spinal cord and carotid artery are so limited that they cannot be viewed as strong conclusions of probability of risk, but rather, as a general guideline for consideration. There is a great need for better reporting standards as noted in the High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic introductory paper. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
5. Stereotactic Body Radiation Therapy for Spinal Metastases: Tumor Control Probability Analyses and Recommended Reporting Standards.
- Author
-
Soltys, Scott G., Grimm, Jimm, Milano, Michael T., Xue, Jinyu, Sahgal, Arjun, Yorke, Ellen, Yamada, Yoshiya, Ding, George X., Li, X. Allen, Lovelock, D. Michael, Jackson, Andrew, Ma, Lijun, El Naqa, Issam, Gibbs, Iris C., Marks, Lawrence B., and Benedict, Stanley
- Subjects
- *
RADIOTHERAPY , *METASTASIS , *DATA extraction , *PROBABILITY theory , *DATA modeling - Abstract
Purpose: We sought to investigate the tumor control probability (TCP) of spinal metastases treated with stereotactic body radiation therapy (SBRT) in 1 to 5 fractions.Methods and Materials: PubMed-indexed articles from 1995 to 2018 were eligible for data extraction if they contained SBRT dosimetric details correlated with actuarial 2-year local tumor control rates. Logistic dose-response models of collected data were compared in terms of physical dose and 3-fraction equivalent dose.Results: Data were extracted from 24 articles with 2619 spinal metastases. Physical dose TCP modeling of 2-year local tumor control from the single-fraction data were compared with data from 2 to 5 fractions, resulting in an estimated α/β = 6 Gy, and this was used to pool data. Acknowledging the uncertainty intrinsic to the data extraction and modeling process, the 90% TCP corresponded to 20 Gy in 1 fraction, 28 Gy in 2 fractions, 33 Gy in 3 fractions, and (with extrapolation) 40 Gy in 5 fractions. The estimated TCP for common fractionation schemes was 82% at 18 Gy, 90% for 20 Gy, and 96% for 24 Gy in a single fraction, 82% for 24 Gy in 2 fractions, and 78% for 27 Gy in 3 fractions.Conclusions: Spinal SBRT with the most common fractionation schemes yields 2-year estimates of local control of 82% to 96%. Given the heterogeneity in the tumor control estimates extracted from the literature, with variability in reporting of dosimetry data and the definition of and statistical methods of reporting tumor control, care should be taken interpreting the resultant model-based estimates. Depending on the clinical intent, the improved TCP with higher dose regimens should be weighed against the potential risks for greater toxicity. We encourage future reports to provide full dosimetric data correlated with tumor local control to allow future efforts of modeling pooled data. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview.
- Author
-
Grimm, Jimm, Marks, Lawrence B., Jackson, Andrew, Kavanagh, Brian D., Xue, Jinyu, and Yorke, Ellen
- Subjects
- *
TREATMENT effectiveness - Published
- 2021
- Full Text
- View/download PDF
7. Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain.
- Author
-
Milano, Michael T., Grimm, Jimm, Niemierko, Andrzej, Soltys, Scott G., Moiseenko, Vitali, Redmond, Kristin J., Yorke, Ellen, Sahgal, Arjun, Xue, Jinyu, Mahadevan, Anand, Muacevic, Alexander, Marks, Lawrence B., and Kleinberg, Lawrence R.
- Subjects
- *
STEREOTACTIC radiosurgery , *BRAIN metastasis , *STEREOTACTIC radiotherapy , *ACOUSTIC neuroma , *CANCER invasiveness - Abstract
Purpose: As part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) after hypofractionated radiation therapy, data from published reports (PubMed indexed 1995-2018) were pooled to identify dosimetric and clinical predictors of radiation-induced brain toxicity after single-fraction stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS).Methods and Materials: Eligible studies provided NTCPs for the endpoints of radionecrosis, edema, or symptoms after cranial SRS/fSRS and quantitative dose-volume metrics. Studies of patients with only glioma, meningioma, vestibular schwannoma, or brainstem targets were excluded. The data summary and analyses focused on arteriovenous malformations (AVM) and brain metastases.Results: Data from 51 reports are summarized. There was wide variability in reported rates of radionecrosis. Available data for SRS/fSRS for brain metastases were more amenable to NTCP modeling than AVM data. In the setting of brain metastases, SRS/fSRS-associated radionecrosis can be difficult to differentiate from tumor progression. For single-fraction SRS to brain metastases, tissue volumes (including target volumes) receiving 12 Gy (V12) of 5 cm3, 10 cm3, or >15 cm3 were associated with risks of symptomatic radionecrosis of approximately 10%, 15%, and 20%, respectively. SRS for AVM was associated with modestly lower rates of symptomatic radionecrosis for equivalent V12. For brain metastases, brain plus target volume V20 (3-fractions) or V24 (5-fractions) <20 cm3 was associated with <10% risk of any necrosis or edema, and <4% risk of radionecrosis requiring resection.Conclusions: The risk of radionecrosis after SRS and fSRS can be modeled as a function of dose and volume treated. The use of fSRS appears to reduce risks of radionecrosis for larger treatment volumes relative to SRS. More standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses that can refine predictive models of brain toxicity risks. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways.
- Author
-
Milano, Michael T., Grimm, Jimm, Soltys, Scott G., Yorke, Ellen, Moiseenko, Vitali, Tomé, Wolfgang A., Sahgal, Arjun, Xue, Jinyu, Ma, Lijun, Solberg, Timothy D., Kirkpatrick, John P., Constine, Louis S., Flickinger, John C., Marks, Lawrence B., and El Naqa, Issam
- Subjects
- *
STEREOTACTIC radiosurgery , *UVEA cancer , *CRANIOPHARYNGIOMA , *SKULL tumors , *OPTIC nerve , *STEREOTACTIC radiotherapy , *VISUAL fields - Abstract
Purpose: Dosimetric and clinical predictors of radiation-induced optic nerve/chiasm neuropathy (RION) after single-fraction stereotactic radiosurgery (SRS) or hypofractionated (2-5 fractions) radiosurgery (fSRS) were analyzed from pooled data that were extracted from published reports (PubMed indexed from 1990 to June 2015). This study was undertaken as part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy, investigating normal tissue complication probability (NTCP) after hypofractionated radiation.Methods and Materials: Eligible studies described dose delivered to optic nerve/chiasm and provided crude or actuarial toxicity risks, with visual endpoints (ie, loss of visual acuity, alterations in visual fields, and/or blindness/complete vision loss). Studies of patients with optic nerve sheath tumors, optic nerve gliomas, or ocular/uveal melanoma were excluded to obviate direct tumor effects on visual outcomes, as were studies not specifying causes of vision loss (ie, tumor progression vs RION).Results: Thirty-four studies (1578 patients) were analyzed. Histologies included pituitary adenoma, cavernous sinus meningioma, craniopharyngioma, and malignant skull base tumors. Prior resection (76% of patients) did not correlate with RION risk (P = .66). Prior irradiation (6% of patients) was associated with a crude 10-fold increased RION risk versus no prior radiation therapy. In patients with no prior radiation therapy receiving SRS/fSRS in 1-5 fractions, optic apparatus maximum point doses resulting in <1% RION risks include 12 Gy in 1 fraction (which is greater than our recommendation of 10 Gy in 1 fraction), 20 Gy in 3 fractions, and 25 Gy in 5 fractions. Omitting multi-fraction data (and thereby eliminating uncertainties associated with dose conversions), a single-fraction dose of 10 Gy was associated with a 1% RION risk. Insufficient details precluded modeling of NTCP risks after prior radiation therapy.Conclusions: Optic apparatus NTCP and tolerance doses after single- and multi-fraction stereotactic radiosurgery are presented. Additional standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses and better define RION NTCP after SRS/fSRS. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Local recurrence patterns after postoperative stereotactic radiation surgery to resected brain metastases: A quantitative analysis to guide target delineation.
- Author
-
Gui, Chengcheng, Moore, Joseph, Grimm, Jimm, Kleinberg, Lawrence, McNutt, Todd, Shen, Colette, Chen, Linda, Bettegowda, Chetan, Lim, Michael, and Redmond, Kristin J.
- Abstract
Abstract Purpose In the treatment of resected metastatic brain disease, a recent phase 3 trial by the North Central Cancer Treatment Group (N107C/CEC.3) surprisingly found that the local control rate for whole-brain radiation therapy was better than that of stereotactic radiation surgery (SRS). To optimize target delineation, we performed a quantitative analysis of local failure patterns after postoperative SRS. Methods and materials Patients with brain metastases who were treated with surgery and SRS to the cavity were evaluated. Local failure was defined by pathologic confirmation or magnetic resonance imaging evidence of progression leading to further overlapping radiation therapy. T1 postgadolinium magnetic resonance imaging scans that were taken preoperatively and at recurrence were co-registered to the simulation computed tomography. Three volumes were compared: (1) Preoperative tumors, (2) resection cavities that were originally contoured as clinical target volumes for SRS, and (3) recurrent tumors. Overlap volume histograms quantified the proximity of the three volumes to the meninges. Results In the cohort of 173 patients, 18 patients experienced local failure in 19 resection cavities. The original SRS target volume overlapped with a median of 69.6% of the recurrent tumor. When the entire preoperative tumor was included, the overlap with the recurrent tumor increased to a median of 76.8%. Recurrent tumors were closer to the meninges than corresponding preoperative tumors (P =.03) but a median 8.2 mm expansion of the target volume from the meninges was needed to increase overlap with the recurrent tumor to 90%. Increases in overlap with the recurrent tumor were achieved most efficiently by uniformly expanding the contoured cavity and a median 2.8 mm expansion covered 90% of the recurrent tumor. Conclusions Our quantitative analysis of recurrence patterns suggests that a larger 3 mm uniform expansion of the SRS target volume substantially increases coverage of the volume that is later occupied by the recurrent tumor and may provide improved local control. The extent of the preoperative tumor in the target volume or expanding the target volume from the meninges provides little benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Estimated Risk Level of Unified Stereotactic Body Radiation Therapy Dose Tolerance Limits for Spinal Cord.
- Author
-
Grimm, Jimm, Sahgal, Arjun, Soltys, Scott G., Luxton, Gary, Patel, Ashish, Herbert, Scott, Xue, Jinyu, Ma, Lijun, Yorke, Ellen, Adler, John R., and Gibbs, Iris C.
- Abstract
A literature review of more than 200 stereotactic body radiation therapy spine articles from the past 20 years found only a single article that provided dose-volume data and outcomes for each spinal cord of a clinical dataset: the Gibbs 2007 article (Gibbs et al, 2007 1 ), which essentially contains the first 100 stereotactic body radiation therapy (SBRT) spine treatments from Stanford University Medical Center. The dataset is modeled and compared in detail to the rest of the literature review, which found 59 dose tolerance limits for the spinal cord in 1-5 fractions. We partitioned these limits into a unified format of high-risk and low-risk dose tolerance limits. To estimate the corresponding risk level of each limit we used the Gibbs 2007 clinical spinal cord dose-volume data for 102 spinal metastases in 74 patients treated by spinal radiosurgery. In all, 50 of the patients were previously irradiated to a median dose of 40 Gy in 2-3 Gy fractions and 3 patients developed treatment-related myelopathy. These dose-volume data were digitized into the dose-volume histogram (DVH) Evaluator software tool where parameters of the probit dose-response model were fitted using the maximum likelihood approach (Jackson et al, 1995 3 ). Based on this limited dataset, for de novo cases the unified low-risk dose tolerance limits yielded an estimated risk of spinal cord injury of ≤1% in 1-5 fractions, and the high-risk limits yielded an estimated risk of ≤3%. The QUANTEC D max limits of 13 Gy in a single fraction and 20 Gy in 3 fractions had less than 1% risk estimated from this dataset, so we consider these among the low-risk limits. In the previously irradiated cohort, the estimated risk levels for 10 and 14 Gy maximum cord dose limits in 5 fractions are 0.4% and 0.6%, respectively. Longer follow-up and more patients are required to improve the risk estimates and provide more complete validation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Introduction and Clinical Overview of the DVH Risk Map.
- Author
-
Asbell, Sucha O., Grimm, Jimm, Xue, Jinyu, Chew, Meng-Sang, and LaCouture, Tamara A.
- Abstract
Radiation oncologists need reliable estimates of risk for various fractionation schemes for all critical anatomical structures throughout the body, in a clinically convenient format. Reliable estimation theory can become fairly complex, however, and estimates of risk continue to evolve as the literature matures. To navigate through this efficiently, a dose-volume histogram (DVH) Risk Map was created, which provides a comparison of radiation tolerance limits as a function of dose, fractionation, volume, and risk level. The graphical portion of the DVH Risk Map helps clinicians to easily visualize the trends, whereas the tabular portion provides quantitative precision for clinical implementation. The DVH Risk Map for rib tolerance from stereotactic ablative body radiotherapy (SABR) and stereotactic body radiation therapy (SBRT) is used as an example in this overview; the 5% and 50% risk levels for 1-5 fractions for 5 different volumes are given. Other articles throughout this issue of Seminars in Radiation Oncology present analysis of new clinical datasets including the DVH Risk Maps for other anatomical structures throughout the body. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Esophageal Dose Tolerance in Patients Treated With Stereotactic Body Radiation Therapy.
- Author
-
Nuyttens, Joost J., Moiseenko, Vitali, McLaughlin, Mark, Jain, Sheena, Herbert, Scott, and Grimm, Jimm
- Abstract
Mediastinal critical structures such as trachea, bronchus, esophagus, and heart are among the dose-limiting factors for stereotactic body radiation therapy (SBRT) to central lung lesions. The purpose of this study was to characterize the risk of esophagitis for patients treated with SBRT and to develop a statistical dose-response model to assess the equivalent uniform dose, D 10% , D 5 cc , D 1 cc , and D max , to the esophagus and the risk of toxicity. Toxicity outcomes of a dose-escalation study of 56 patients who had taken CyberKnife treatment from 45-60 Gy in 3-7 fractions at the Erasmus MC-Daniel den Hoed Cancer Center were utilized to create the dose-response model for esophagus. A total of 5 grade 2 esophageal complications were reported (Common Terminology Criteria for Adverse Events version 3.0); 4 complications were early effects and 1 complication was a late effect. All analyses were performed in terms of 5-fraction equivalent dosing. According to our study, D 1 cc at a dose of 32.9 Gy and D max dose of 43.4 Gy corresponded to a complication probability of 50% for grade 2 toxicity. In this series of 58 CyberKnife mediastinal lung cases, no grade 3 or higher esophageal toxicity occurred. Our estimates of esophageal toxicity are compared with the data in the literature. Further research needs to be performed to establish more reliable dose limits as longer follow-up and toxicity outcomes are reported in patients treated with SBRT for central lung lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Multisession Radiosurgery for Hearing Preservation.
- Author
-
Rashid, Abdul, Karam, Sana D., Rashid, Beenish, Kim, Jeffrey H., Pang, Dalong, Jean, Walter, Grimm, Jimm, and Collins, Sean P.
- Abstract
Clinically relevant dose-tolerance limits with reliable estimates of risk in 1-5 fractions for cochlea are still unknown. Timmerman׳s limits from the October 2008 issue of Seminars in Radiation Oncology have served as the basis for clinical practice, augmented by updated constraints in TG-101 and QUANTEC, but the corresponding estimates of risk have not yet been well-reported. A total of 37 acoustic neuroma CyberKnife cases from Medstar Georgetown University Hospital treated in 3 or 5 fractions were combined with single-fraction Gamma Knife data from the 69 cases in Timmer 2009 to form an aggregate dataset of 106 cochlea cases treated in 1-5 fractions. Probit dose-response modeling was performed in the DVH Evaluator software to estimate normal tissue complication probability. QUANTEC recommends keeping single-fraction maximum dose to the cochlea less than 14 Gy to maintain less than 25% risk of serviceable hearing loss, and our 17.9% risk estimate for 14 Gy in 1 fraction is within their predicted range. In 5 fractions, our estimate of the Timmerman 27.5 Gy maximum cochlea dose limit was 17.4%. For cases in which lower risk is required, the Timmerman 12 Gy in 1 fraction and the TG-101 limit of 25 Gy in 5 fractions had an estimated risk level of 11.8% and 13.8%, respectively. High-risk and low-risk dose tolerance with risk estimates in 1-5 fractions are all presented. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Dose-Response Model for Chest Wall Tolerance of Stereotactic Body Radiation Therapy.
- Author
-
Kimsey, Frank, McKay, Jesse, Gefter, Jeffrey, Milano, Michael T., Moiseenko, Vitali, Grimm, Jimm, and Berg, Ronald
- Abstract
Many recent studies have described rib fractures and chest wall pain following stereotactic body radiation therapy (SBRT). Although these toxicities generally are not life-threatening, the chest wall and ribs are considered dose-limiting tissues because of the potential effect on patients׳ quality of life. Few studies have reported dose-response models that can provide quantitative estimates of risk as a function of dose and volume. Notably, Memorial Sloan Kettering Cancer Center (Mutter et al 8 ) analyzed grade 2 or higher chest wall toxicity in a cohort of 126 patients treated with linear accelerator–based SBRT; the authors provided detailed dose-volume histogram (DVH) data to allow for pooled analyses. We pooled these 126 patients with an additional 44 patients treated with CyberKnife at the Erlanger Medical Center to create an updated dose-response model for chest wall tolerance. In the aggregate analysis, the 10% risk level for grade 2 or higher complications for D 70 cc was 16.2 Gy in 4 fractions, and the 50% risk level was D 70 cc = 65.1 Gy in 4 fractions. For D 2 cc , the 10% and 50% risk levels in 4 fractions were 43.0 Gy and 87.9 Gy, respectively. These dose-tolerance limits may help quantify chest wall toxicity risks. Further research continues to determine more accurate estimates of grade 3 risk levels. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. In Reply to Song et al, and In Reply to Brown and Carlson.
- Author
-
Grimm, Jimm, Mahadevan, Anand, Brown, J. Martin, Carlson, David J., Brenner, David J., Lo, Simon S., Song, Chang W., and Cho, L. Chinsoo
- Subjects
- *
SONGS - Abstract
In Reply to Song et al, and In Reply to Brown and Carlson. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
16. Low toxicity for lung tumors near the mediastinum treated with stereotactic body radiation therapy.
- Author
-
Srivastava, Roma, Asbell, Sucha O., LaCouture, Tamara, Kramer, Noel, Pahlajani, Niraj, Xue, Jinyu, Ahmad, Nazish, Chen, Yan, Croce, Raymond, and Grimm, Jimm
- Subjects
STEREOTACTIC radiotherapy ,MEDIASTINUM diseases ,LUNG cancer patients ,DRUG tolerance ,DOSE-effect relationship in pharmacology ,FOLLOW-up studies (Medicine) ,THERAPEUTICS - Abstract
Abstract: Purpose: To report the local control, survival, and low toxicity observed at the Cooper University Hospital CyberKnife Center post stereotactic body radiation therapy (SBRT) in the treatment of lung tumors near the mediastinum. Methods and Materials: Twenty-four medically inoperable lung cancer patients with tumors near the mediastinum were treated using the Accuray CyberKnife system (Accuray, Sunnyvale, CA) with Monte Carlo dose calculations and heterogeneity corrections from July 2008 to May 2010. The prescription dose ranged from 28.5 Gy to 60 Gy in 3-5 fractions. For conventional fractionation schemes, Emami et al
1 organized the dose tolerance limits into a unified format for clinical utility and partitioned them into 2 risk levels (5% and 50%) with preset volumes for most critical structures throughout the body. In contrast, statistical SBRT dose tolerance limits for mediastinal structures have not been established yet. We have sufficient experience at least to begin organizing a unified format with low-risk and high-risk partitions and preset volumes for 1-5 fractions exposing mediastinal structures. With the help of the (dose-volume histogram) DVH Evaluator, a software tool developed by our senior author, each treatment plan was assessed for safety and feasibility prior to treatment. The DVH Evaluator was also used to analyze the follow-up data and to create graphs of risk, called DVH Risk Maps, superimposing clinical data onto the unified SBRT dose tolerance limits. Results: It was not feasible to prescribe the doses of peripheral lung lesions for all tumors near the mediastinum because of known toxicity. The crude local tumor control rate achieved in our series was 92%. Median survival was 26.8 months for the primary lung cases and 9.6 months for the metastatic cases. No patients experienced grade 3 or higher toxicities. Conclusions: We affirm that SBRT is feasible in the treatment of centrally located lung cancers when the dose tolerance limits of critical structures are diligently respected. The low adverse event rates that we have experienced, combined with a good local tumor control rate, are encouraging. [Copyright &y& Elsevier]- Published
- 2013
- Full Text
- View/download PDF
17. A Primer on Dose-Response Data Modeling in Radiation Therapy.
- Author
-
Moiseenko, Vitali, Marks, Lawrence B., Grimm, Jimm, Jackson, Andrew, Milano, Michael T., Hattangadi-Gluth, Jona A., Huynh-Le, Minh-Phuong, Pettersson, Niclas, Yorke, Ellen, and El Naqa, Issam
- Subjects
- *
RADIOTHERAPY , *MAXIMUM likelihood statistics , *DATA modeling , *CONFIDENCE intervals , *PREDICTION models - Abstract
An overview of common approaches used to assess a dose response for radiation therapy-associated endpoints is presented, using lung toxicity data sets analyzed as a part of the High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic effort as an example. Each component presented (eg, data-driven analysis, dose-response analysis, and calculating uncertainties on model prediction) is addressed using established approaches. Specifically, the maximum likelihood method was used to calculate best parameter values of the commonly used logistic model, the profile-likelihood to calculate confidence intervals on model parameters, and the likelihood ratio to determine whether the observed data fit is statistically significant. The bootstrap method was used to calculate confidence intervals for model predictions. Correlated behavior of model parameters and implication for interpreting dose response are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer.
- Author
-
Mahadevan, Anand, Moningi, Shalini, Grimm, Jimm, Li, X. Allen, Forster, Kenneth M., Palta, Manisha, Prior, Phillip, Goodman, Karyn A., Narang, Amol, Heron, Dwight E., Lo, Simon S., Urbanic, James, and Herman, Joseph M.
- Subjects
- *
CANCER radiotherapy , *PANCREATECTOMY , *IMAGE-guided radiation therapy , *PANCREATIC cancer , *RADIOTHERAPY , *TUMORS - Abstract
Purpose: Stereotactic body radiation therapy (SBRT) and stereotactic ablative body radiation therapy is being increasingly used for pancreatic cancer (PCa), particularly in patients with locally advanced and borderline resectable disease. A wide variety of dose fractionation schemes have been reported in the literature. This HyTEC review uses tumor control probability models to evaluate the comparative effectiveness of the various SBRT treatment regimens used in the treatment of patients with localized PCa.Methods and Materials: A PubMed search was performed to review the published literature on the use of hypofractionated SBRT (usually in 1-5 fractions) for PCa in various clinical scenarios (eg, preoperative [neoadjuvant], borderline resectable, and locally advanced PCa). The linear quadratic model with α/β= 10 Gy was used to address differences in fractionation. Logistic tumor control probability models were generated using maximum likelihood parameter fitting.Results: After converting to 3-fraction equivalent doses, the pooled reported data and associated models suggests that 1-year local control (LC) without surgery is ≈79% to 86% after the equivalent of 30 to 36 Gy in 3 fractions, showing a dose response in the range of 25 to 36 Gy, and decreasing to less than 70% 1-year LC at doses below 24 Gy in 3 fractions. The 33 Gy in 5 fraction regimen (Alliance A021501) corresponds to 28.2 Gy in 3 fractions, for which the HyTEC pooled model had 77% 1-year LC without surgery. Above an equivalent dose of 28 Gy in 3 fractions, with margin-negative resection the 1-year LC exceeded 90%.Conclusions: Pooled analyses of reported tumor control probabilities for commonly used SBRT dose-fractionation schedules for PCa suggests a dose response. These findings should be viewed with caution given the challenges and limitations of this review. Additional data are needed to better understand the dose or fractionation-response of SBRT for PCa. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
19. Head and Neck Tumor Control Probability: Radiation Dose-Volume Effects in Stereotactic Body Radiation Therapy for Locally Recurrent Previously-Irradiated Head and Neck Cancer: Report of the AAPM Working Group.
- Author
-
Vargo, John A., Moiseenko, Vitali, Grimm, Jimm, Caudell, Jimmy, Clump, David A., Yorke, Ellen, Xue, Jinyu, Vinogradskiy, Yevgeniy, Moros, Eduardo G., Mavroidis, Panayiotis, Jain, Sheena, El Naqa, Issam, Marks, Lawrence B., and Heron, Dwight E.
- Subjects
- *
HEAD tumors , *NECK tumors , *RADIOTHERAPY , *EXPERIMENTAL design , *PROBABILITY theory - Abstract
Purpose: Stereotactic body radiation therapy (SBRT) has emerged as a viable reirradiation strategy for locally recurrent previously-irradiated head and neck cancer. Doses in the literature have varied, which challenges clinical application of SBRT as well as clinical trial design.Material& Methods: A working group was formed through the American Association of Physicists in Medicine to study tumor control probabilities for SBRT in head and neck cancer. We herein present a systematic review of the available literature addressing the dose/volume data for tumor control probability with SBRT in patients with locally recurrent previously-irradiated head and neck cancer. Dose-response models are generated that present tumor control probability as a function of dose.Results: Data from more than 300 cases in 8 publications suggest that there is a dose-response relationship, with superior local control and possibly improved overall survival for doses of 35 to 45 Gy (in 5 fractions) compared with <30 Gy.Conclusion: Stereotactic body radiation therapy doses equivalent to 5-fraction doses of 40 to 50 Gy are suggested for retreatment. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
20. Hypofractionated Stereotactic Radiation Therapy Dosimetric Tolerances for the Inferior Aspect of the Brachial Plexus: A Systematic Review.
- Author
-
Milano, Michael T., Doucette, Christopher, Mavroidis, Panayiotis, Yorke, Ellen, Ryckman, Jeff, Mahadevan, Anand, Kapitanova, Irina, Kong, Feng-Ming (Spring), Grimm, Jimm, and Marks, Lawrence B.
- Subjects
- *
BRACHIAL plexus , *MEDICAL dosimetry , *STEREOTACTIC radiotherapy , *RADIOTHERAPY , *BRACHIAL plexus neuropathies - Abstract
We sought to systematically review and summarize dosimetric factors associated with radiation-induced brachial plexopathy (RIBP) after stereotactic body radiation therapy (SBRT) or hypofractionated image guided radiation therapy (HIGRT). From published studies identified from searches of PubMed and Embase databases, data quantifying risks of RIBP after 1- to 10-fraction SBRT/HIGRT were extracted and summarized. Published studies have reported <10% risks of RIBP with maximum doses (D max) to the inferior aspect of the brachial plexus of 32 Gy in 5 fractions and 25 Gy in 3 fractions. For 10-fraction HIGRT, risks of RIBP appear to be low with D max < 40 to 50 Gy. For a given dose value, greater risks are anticipated with point volume-based metrics (ie, D 0.03-0.035cc : minimum dose to hottest 0.03-0.035 cc) versus D max. With SBRT/HIGRT, there were insufficient published data to predict risks of RIBP relative to brachial plexus dose-volume exposure. Minimizing maximum doses and possibly volume exposure of the brachial plexus can reduce risks of RIBP after SBRT/HIGRT. Further study is needed to better understand the effect of volume exposure on the brachial plexus and whether there are location-specific susceptibilities along or within the brachial plexus structure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Dose Tolerance for Stereotactic Body Radiation Therapy.
- Author
-
Grimm, Jimm
- Published
- 2016
- Full Text
- View/download PDF
22. Normal tissue complication probability of vertebral compression fracture after stereotactic body radiotherapy for de novo spine metastasis.
- Author
-
Chen, Xuguang, Gui, Chengcheng, Grimm, Jimm, Huang, Ellen, Kleinberg, Lawrence, Lo, Larry, Sciubba, Daniel, Khan, Majid, and Redmond, Kristin J.
- Subjects
- *
STEREOTACTIC radiotherapy , *VERTEBRAL fractures , *STEREOTACTIC radiosurgery , *SPINE , *KYPHOPLASTY , *PROPORTIONAL hazards models , *SPINAL instability , *STATURE - Abstract
• Hypofractionated SBRT for de novo spinal metastases has 1-year local control of up to 90% and VCF incidence of 4.6%. • Doses to 80% and 50% of PTV are most predictive of VCF risk. • On multivariate analysis, every Gy increase in PTV D80% (in 3-fraction equivalent dose) is associated with 11% increase in VCF risk. • Minimizing post-SBRT VCF risk may require re-evaluation of the consensus contouring guidelines and novel radiation planning techniques. Stereotactic body radiotherapy (SBRT) for spine metastases is associated with post-treatment vertebral compression fracture (VCF). The purpose of this study is to identify clinical and radiation planning characteristics that predict post-SBRT VCF through a novel normal tissue complication probability (NTCP) analysis. Patients with de novo spine metastases treated with SBRT between 2009 and 2018 at a single institution were included. Those who had surgical stabilization or radiation to the same site prior to SBRT were excluded. VCF was defined as new development or progression of existing vertebral body height loss not attributable to tumor growth. Probit NTCP models were constructed and fitted using a maximum likelihood approach. A multivariate proportional hazard model was used to estimate time to VCF using the Fine and Gray method. Three hundred and two vertebral segments from 193 patients were treated with a median dose of 24 Gy in 3 fractions (range 15–30 Gy in 1–5 fractions). With a median follow up of 13.9 months, local control was 89.3% at 1 year. A total of 26 SBRT-induced VCFs were observed, with 1 and 2-year cumulative incidences of 4.6% and 6.7%. NTCP modeling demonstrated a steep response of VCF risk to the dose to 80% and 50% volume of the planning target volume (PTV D80% and D50%), but not maximum dose or dose to 1 cc or 10% of PTV. D80% of 25 Gy and D50% of 28 Gy in 3 fractions corresponded to 10% VCF risk. On multivariate analysis, lower body mass index (HR 0.90 per unit increase, p = 0.04), total spinal instability neoplastic score (SINS, HR 2.44 unstable vs stable, p = 0.04), and PTV D80% (HR 1.11 for every Gy increase, p = 0.003) were associated with increased VCF risk. SBRT provides excellent tumor control for spinal metastases and is associated with low rate of VCF in our cohort. NTCP modeling suggests that the larger volume of spine receiving lower doses are more closely associated with post-SBRT VCF than high dose regions. Under current target delineation methods, common SBRT regimens such as 24 Gy in 2 fractions or 27 Gy in 3 fractions may be inherently associated with VCF risk of 10% or greater. Consensus contouring guidelines should be reevaluated to minimize the volume of irradiated spine in light of these new data. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. In Reply to Onjukka et al.
- Author
-
Milano, Michael T., Mavroidis, Panayiotis, Yorke, Ellen, Ryckman, Jeff, Kong, Feng-Ming (Spring), Grimm, Jimm, and Marks, Lawrence B.
- Published
- 2024
- Full Text
- View/download PDF
24. Quantifying Rigid and Nonrigid Motion of Liver Tumors During Stereotactic Body Radiation Therapy.
- Author
-
Qianyi Xu, Hanna, George, Grimm, Jimm, Kubicek, Gregory, Pahlajani, Niraj, Asbell, Sucha, Jiajin Fan, Yan Chen, and LaCouture, Tamara
- Subjects
- *
LIVER tumors , *TUMOR treatment , *CANCER radiotherapy , *CANCER cell motility , *STEREOTACTIC radiotherapy , *FIDUCIAL markers (Imaging systems) , *LEAST squares - Abstract
Purpose To quantify rigid and nonrigid motion of liver tumors using reconstructed 3-dimensional (3D) fiducials from stereo imaging during CyberKnife-based stereotactic body radiation therapy (SBRT). Methods and Materials Twenty-three liver patients treated with 3 fractions of SBRT were used in this study. After 2 orthogonal kilovoltage images were taken during treatment, the 3D locations of the fiducials were generated by the CyberKnife system and validated using geometric derivations. A total of 4824 pairs of kilovoltage images from start to end of treatment were analyzed. For rigid motion, the rotational angles and translational shifts were reported by aligning 3D fiducial groups from different image pairs, using least-squares fitting. For nonrigid motion, we quantified interfractional tumor volume variations by using the proportional volume derived from the fiducials, which correlates to the sum of interfiducial distances. The individual fiducial displacements were also reported (1) after rigid corrections and (2) without angle corrections. Results The proportional volume derived by the fiducials demonstrated a volume-increasing trend in the second (101.9% ± 3.6%) and third (101.0 ± 5.9%) fractions among most patients, possibly due to radiation-induced edema. For all patients, the translational shifts in left-right, anteroposterior, and superoinferior directions were 2.1 ± 2.3 mm, 2.9 ± 2.8 mm, and 6.4 ± 5.5 mm, respectively. The greatest translational shifts occurred in the superoinferior direction, likely due to respiratory motion from the diaphragm. The rotational angles in roll, pitch, and yaw were 1.2° ± 1.8°, 1.8° ± 2.4°, and 1.7° ± 2.1°, respectively. The 3D individual fiducial displacements with rigid corrections were 0.2 ± 0.2 mm and increased to 0.5 ± 0.4 mm without rotational corrections. Conclusions Accurate 3D locations of internal fiducials can be reconstructed from stereo imaging during treatment. As an effective surrogate to tumor motion, fiducials provide a close estimation of both rigid and nonrigid motion of liver tumors. The reported displacements could be further utilized for tumor margin definition and motion management in conventional linear accelerator-based liver SBRT. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
25. The Art of Radiation Therapy: The Necessary Risk of Radiation Necrosis for Durable Control of Brain Metastases.
- Author
-
Milano, Michael T., Soltys, Scott G., Marks, Lawrence B., Heron, Dwight E., Yorke, Ellen, Grimm, Jimm, Jackson, Andrew, Mihai, Alina, Timmerman, Robert D., Xue, Jinyu, Kavanagh, Brian D., and Redmond, Kristin J.
- Subjects
- *
EXPRESSIVE arts therapy , *ART therapy , *RADIOTHERAPY , *NECROSIS , *RADIATION - Published
- 2023
- Full Text
- View/download PDF
26. Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors.
- Author
-
Stumpf, Priscilla K., Yorke, Ellen D., El Naqa, Issam, Cuneo, Kyle C., Grimm, Jimm, and Goodman, Karyn A.
- Subjects
- *
RADIOTHERAPY , *MAXIMUM likelihood statistics , *TREATMENT effectiveness , *PROBABILITY theory , *RADIATION doses , *ADRENAL tumors - Abstract
Purpose: Stereotactic body radiation therapy (SBRT) in the management of adrenal metastases is emerging as a well-tolerated, effective method of treatment for patients with limited metastatic disease. SBRT planning and treatment utilization are widely variable, and publications report heterogeneous radiation dose fractionation schemes and treatment outcomes. The objective of this analysis was to review the current literature on SBRT for adrenal metastases and to develop treatment guidelines and a model for tumor control probability of SBRT for adrenal metastases based on these publications.Methods and Materials: A literature search of all studies on SBRT for adrenal metastases published from 2008 to 2017 was performed, and outcomes in these studies were reviewed. Local control (LC) rates were fit to a statistically significant Poisson model using maximum likelihood estimation techniques.Results: One-year LC greater than 95% was achieved at an approximated biological equivalent dose with α/β = 10 Gy of 116.4 Gy.Conclusions: While respecting normal tissue tolerances, tumor doses greater than or equal to a biological equivalent dose with α/β = 10 Gy of 116.4 Gy are recommended to achieve high LC. Further studies following unified reporting standards are needed for more robust prediction. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
27. Stereotactic Radiosurgery for Vestibular Schwannomas: Tumor Control Probability Analyses and Recommended Reporting Standards.
- Author
-
Soltys, Scott G., Milano, Michael T., Xue, Jinyu, Tomé, Wolfgang A., Yorke, Ellen, Sheehan, Jason, Ding, George X., Kirkpatrick, John P., Ma, Lijun, Sahgal, Arjun, Solberg, Timothy, Adler, John, Grimm, Jimm, and El Naqa, Issam
- Subjects
- *
STEREOTACTIC radiosurgery , *SCHWANNOMAS , *ACOUSTIC neuroma , *DATA extraction , *TUMORS - Abstract
Purpose: We sought to investigate the tumor control probability (TCP) of vestibular schwannomas after single-fraction stereotactic radiosurgery (SRS) or hypofractionated SRS over 2 to 5 fractions (fSRS).Methods and Materials: Studies (PubMed indexed from 1993-2017) were eligible for data extraction if they contained dosimetric details of SRS/fSRS correlated with local tumor control. The rate of tumor control at 5 years (or at 3 years if 5-year data were not available) were collated. Poisson modeling estimated the TCP per equivalent dose in 2 Gy per fraction (EQD2) and in 1, 3, and 5 fractions.Results: Data were extracted from 35 publications containing a total of 5162 patients. TCP modeling was limited by the absence of analyzable data of <11 Gy in a single-fraction, variability in definition of "tumor control," and by lack of significant increase in TCP for doses >12 Gy. Using linear-quadratic-based dose conversion, the 3- to 5-year TCP was estimated at 95% at an EQD2 of 25 Gy, corresponding to 1-, 3-, and 5-fraction doses of 13.8 Gy, 19.2 Gy, and 21.5 Gy, respectively. Single-fraction doses of 10 Gy, 11 Gy, 12 Gy, and 13 Gy predicted a TCP of 85.0%, 88.4%, 91.2%, and 93.5%, respectively. For fSRS, 18 Gy in 3 fractions (EQD2 of 23.0 Gy) and 25 Gy in 5 fractions (EQD2 of 30.2 Gy) corresponded to TCP of 93.6% and 97.2%. Overall, the quality of dosimetric reporting was poor; recommended reporting guidelines are presented.Conclusions: With current typical SRS doses of 12 Gy in 1 fraction, 18 Gy in 3 fractions, and 25 Gy in 5 fractions, 3- to 5-year TCP exceeds 91%. To improve pooled data analyses to optimize treatment outcomes for patients with vestibular schwannoma, future reports of SRS should include complete dosimetric details with well-defined tumor control and toxicity endpoints. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
28. Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases.
- Author
-
Redmond, Kristin J., Gui, Chengcheng, Benedict, Stanley, Milano, Michael T., Grimm, Jimm, Vargo, J. Austin, Soltys, Scott G., Yorke, Ellen, Jackson, Andrew, El Naqa, Issam, Marks, Lawrence B., Xue, Jinyu, Heron, Dwight E., and Kleinberg, Lawrence R.
- Subjects
- *
STEREOTACTIC radiosurgery , *BRAIN metastasis , *STEREOTACTIC radiotherapy , *PROBABILITY theory , *TUMORS - Abstract
Purpose: As part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy, tumor control probability (TCP) after stereotactic radiosurgery (SRS) and fractionated stereotactic radiosurgery (fSRS) for brain metastases was modeled based on pooled dosimetric and clinical data from published English-language literature.Methods and Materials: PubMed-indexed studies published between January 1995 and September 2017 were used to evaluate dosimetric and clinical predictors of TCP after SRS or fSRS for brain metastases. Eligible studies had ≥10 patients and included detailed dose-fractionation data with corresponding ≥1-year local control (LC) data, typically evaluated as a >20% increase in diameter of the targeted lesion using the pre-SRS diameter as a reference.Results: Of 2951 potentially eligible manuscripts, 56 included sufficient dose-volume data for analyses. Accepting that necrosis and pseudoprogression can complicate the assessment of LC, for tumors ≤20 mm, single-fraction doses of 18 and 24 Gy corresponded with >85% and 95% 1-year LC rates, respectively. For tumors 21 to 30 mm, an 18 Gy single-fraction dose was associated with 75% LC. For tumors 31 to 40 mm, a 15 Gy single-fraction dose yielded ∼69% LC. For 3- to 5-fraction fSRS using doses in the range of 27 to 35 Gy, 80% 1-year LC has been achieved for tumors of 21 to 40 mm in diameter.Conclusions: TCP for SRS and fSRS are presented. For small lesions ≤20 mm, single doses of ≈18 Gy appear generally associated with excellent rates of LC; for melanoma, higher doses seem warranted. For larger lesions >20 mm, local control rates appear to be ≈ 70% to 75% with usual doses of 15 to 18 Gy, and in this setting, fSRS regimens should be considered. Greater consistency in reporting of dosimetric and LC data is needed to facilitate future pooled analyses. As systemic and biologic therapies evolve, updated analyses will be needed to further assess the necessity, efficacy, and toxicity of SRS and fSRS. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
29. Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response.
- Author
-
Wang, Kyle, Mavroidis, Panayiotis, Royce, Trevor J., Falchook, Aaron D., Collins, Sean P., Sapareto, Stephen, Sheets, Nathan C., Fuller, Donald B., El Naqa, Issam, Yorke, Ellen, Grimm, Jimm, Jackson, Andrew, and Chen, Ronald C.
- Subjects
- *
RADIOTHERAPY , *CANCER radiotherapy , *PROSTATE , *QUALITY of life , *PROSTATE cancer - Abstract
Purpose: Ultrahypofractionationed radiation therapy for prostate cancer is increasingly studied and adopted. The American Association of Physicists in Medicine Working Group on Biological Effects of Hypofractionated Radiotherapy therefore aimed to review studies examining toxicity and quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer and model its effect.Methods and Materials: We performed a systematic PubMed search of prostate SBRT studies published between 2001 and 2018. Those that analyzed factors associated with late urinary, bowel, or sexual toxicity and/or quality of life were included and reviewed. Normal tissue complication probability modelling was performed on studies that contained detailed dose/volume and outcome data.Results: We found 13 studies that examined urinary effects, 6 that examined bowel effects, and 4 that examined sexual effects. Most studies included patients with low-intermediate risk prostate cancer treated to 35-40 Gy. Most patients were treated with 5 fractions, with several centers using 4 fractions. Endpoints were heterogeneous and included both physician-scored toxicity and patient-reported quality of life. Most toxicities were mild-moderate (eg, grade 1-2) with a very low overall incidence of severe toxicity (eg, grade 3 or higher, usually <3%). Side effects were associated with both dosimetric and non-dosimetric factors.Conclusions: Prostate SBRT appears to be overall well tolerated, with determinants of toxicity that include dosimetric factors and patient factors. Suggested dose constraints include bladder V(Rx Dose)Gy <5-10 cc, urethra Dmax <38-42 Gy, and rectum Dmax <35-38 Gy, though current data do not offer firm guidance on tolerance doses. Several areas for future research are suggested. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
30. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
- Author
-
Royce, Trevor J., Mavroidis, Panayiotis, Wang, Kyle, Falchook, Aaron D., Sheets, Nathan C., Fuller, Donald B., Collins, Sean P., El Naqa, Issam, Song, Daniel Y., Ding, George X., Nahum, Alan E., Jackson, Andrew, Grimm, Jimm, Yorke, Ellen, and Chen, Ronald C.
- Subjects
- *
CANCER radiotherapy , *PHYSIOLOGICAL effects of radiation , *DRUG efficacy , *RADIOTHERAPY , *CANCER relapse - Abstract
Purpose: Dose escalation improves localized prostate cancer disease control, and moderately hypofractionated external beam radiation is noninferior to conventional fractionation. The evolving treatment approach of ultrahypofractionation with stereotactic body radiation therapy (SBRT) allows possible further biological dose escalation (biologically equivalent dose [BED]) and shortened treatment time.Methods and Materials: The American Association of Physicists in Medicine Working Group on Biological Effects of Hypofractionated Radiation Therapy/SBRT included a subgroup to study the prostate tumor control probability (TCP) with SBRT. We performed a systematic review of the available literature and created a dose-response TCP model for the endpoint of freedom from biochemical relapse. Results were stratified by prostate cancer risk group.Results: Twenty-five published cohorts were identified for inclusion, with a total of 4821 patients (2235 with low-risk, 1894 with intermediate-risk, and 446 with high-risk disease, when reported) treated with a variety of dose/fractionation schemes, permitting dose-response modeling. Five studies had a median follow-up of more than 5 years. Dosing regimens ranged from 32 to 50 Gy in 4 to 5 fractions, with total BED (α/β = 1.5 Gy) between 183.1 and 383.3 Gy. At 5 years, we found that in patients with low-intermediate risk disease, an equivalent doses of 2 Gy per fraction (EQD2) of 71 Gy (31.7 Gy in 5 fractions) achieved a TCP of 90% and an EQD2 of 90 Gy (36.1 Gy in 5 fractions) achieved a TCP of 95%. In patients with high-risk disease, an EQD2 of 97 Gy (37.6 Gy in 5 fractions) can achieve a TCP of 90% and an EQD2 of 102 Gy (38.7 Gy in 5 fractions) can achieve a TCP of 95%.Conclusions: We found significant variation in the published literature on target delineation, margins used, dose/fractionation, and treatment schedule. Despite this variation, TCP was excellent. Most prescription doses range from 35 to 40 Gy, delivered in 4 to 5 fractions. The literature did not provide detailed dose-volume data, and our dosimetric analysis was constrained to prescription doses. There are many areas in need of continued research as SBRT continues to evolve as a treatment modality for prostate cancer, including the durability of local control with longer follow-up across risk groups, the efficacy and safety of SBRT as a boost to intensity modulated radiation therapy (IMRT), and the impact of incorporating novel imaging techniques into treatment planning. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
31. Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy.
- Author
-
Sahgal, Arjun, Chang, Joe H., Ma, Lijun, Marks, Lawrence B., Milano, Michael T., Medin, Paul, Niemierko, Andrzej, Soltys, Scott G., Tomé, Wolfgang A., Wong, C. Shun, Yorke, Ellen, Grimm, Jimm, and Jackson, Andrew
- Subjects
- *
SPINAL cord , *RADIOTHERAPY , *SPINAL cord diseases - Abstract
Spinal cord tolerance data for stereotactic body radiation therapy (SBRT) were extracted from published reports, reviewed, and modelled. For de novo SBRT delivered in 1 to 5 fractions, the following spinal cord point maximum doses (Dmax) are estimated to be associated with a 1% to 5% risk of radiation myelopathy (RM): 12.4 to 14.0 Gy in 1 fraction, 17.0 Gy in 2 fractions, 20.3 Gy in 3 fractions, 23.0 Gy in 4 fractions, and 25.3 Gy in 5 fractions. For reirradiation SBRT delivered in 1 to 5 fractions, reported factors associated with a lower risk of RM include cumulative thecal sac equivalent dose in 2 Gy fractions with an alpha/beta of 2 (EQD22) Dmax ≤70 Gy; SBRT thecal sac EQD22 Dmax ≤25 Gy, thecal sac SBRT EQD22 Dmax to cumulative EQD22 Dmax ratio ≤0.5, and a minimum time interval to reirradiation of ≥5 months. Larger studies containing complete institutional cohorts with dosimetric data of patients treated with spine SBRT, with and without RM, are required to refine RM risk estimates. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death.
- Author
-
Song, Chang W., Glatstein, Eli, Marks, Lawrence B., Emami, Bahman, Grimm, Jimm, Sperduto, Paul W., Kim, Mi-Sook, Hui, Susanta, Dusenbery, Kathryn E., and Cho, L. Chinsoo
- Subjects
- *
STEREOTAXIC techniques , *CELL death , *RADIOTHERAPY , *IRRADIATION , *BLOOD vessels - Abstract
Purpose: To review the radiobiological mechanisms of stereotactic body radiation therapy stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS).Methods and Materials: We reviewed previous reports and recent observations on the effects of high-dose irradiation on tumor cell survival, tumor vasculature, and antitumor immunity. We then assessed the potential implications of these biological changes associated with SBRT and SRS.Results: Irradiation with doses higher than approximately 10 Gy/fraction causes significant vascular injury in tumors, leading to secondary tumor cell death. Irradiation of tumors with high doses has also been reported to increase the antitumor immunity, and various approaches are being investigated to further elevate antitumor immunity. The mechanism of normal tissue damage by high-dose irradiation needs to be further investigated.Conclusions: In addition to directly killing tumor cells, high-dose irradiation used in SBRT and SRS induces indirect tumor cell death via vascular damage and antitumor immunity. Further studies are warranted to better understand the biological mechanisms underlying the high efficacy of clinical SBRT and SRS and to further improve the efficacy of SBRT and SRS. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
33. Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?
- Author
-
Kong, Feng-Ming (Spring), Moiseenko, Vitali, Zhao, Jing, Milano, Michael T., Li, Ling, Rimner, Andreas, Das, Shiva, Li, X. Allen, Miften, Moyed, Liao, ZhongXing, Martel, Mary, Bentzen, Soren M., Jackson, Andrew, Grimm, Jimm, Marks, Lawrence B., and Yorke, Ellen
- Subjects
- *
INTERSTITIAL lung diseases , *LUNGS , *NON-small-cell lung carcinoma , *RADIOTHERAPY , *PULMONARY fibrosis , *IMAGE-guided radiation therapy - Abstract
Purpose: Stereotactic body radiation therapy (SBRT) has become the standard of care for inoperable early-stage non-small cell lung cancer and is often used for recurrent lung cancer and pulmonary metastases. Radiation-induced lung toxicity (RILT), including radiation pneumonitis and pulmonary fibrosis, is a major concern for which it is important to understand dosimetric and clinical predictors.Methods and Materials: This study was undertaken through the American Association of Physicists in Medicine's Working Group on Biological Effects of Stereotactic Body Radiotherapy. Data from studies of lung SBRT published through the summer of 2016 that provided detailed information about RILT were analyzed.Results: Ninety-seven studies were ultimately considered. Definitions of the risk organ and complication endpoints as well as dose-volume information presented varied among studies. The risk of RILT, including radiation pneumonitis and pulmonary fibrosis, was reported to be associated with the size and location of the tumor. Patients with interstitial lung disease appear to be especially susceptible to severe RILT. A variety of dosimetric parameters were reported to be associated with RILT. There was no apparent threshold "tolerance dose-volume" level. However, most studies noted safe treatment with a rate of symptomatic RILT of <10% to 15% after lung SBRT with a mean lung dose (MLD) of the combined lungs ≤8 Gy in 3 to 5 fractions and the percent of total lung volume receiving more than 20 Gy (V20) <10% to 15%.Conclusions: To allow more rigorous analysis of this complication, future studies should standardize reporting by including standardized endpoint and volume definitions and providing dose-volume information for all patients, with and without RILT. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
34. Radiation Dose-Volume Effects for Liver SBRT.
- Author
-
Miften, Moyed, Vinogradskiy, Yevgeniy, Moiseenko, Vitali, Grimm, Jimm, Yorke, Ellen, Jackson, Andrew, Tomé, Wolfgang A., Ten Haken, Randall K., Ohri, Nitin, Méndez Romero, Alejandra, Goodman, Karyn A., Marks, Lawrence B., Kavanagh, Brian, and Dawson, Laura A.
- Subjects
- *
HEPATOTOXICOLOGY , *LIVER cancer , *LIVER , *RADIATION , *METASTASIS - Abstract
Stereotactic body radiation therapy (SBRT) has emerged as an effective, noninvasive treatment option for primary liver cancer and metastatic disease occurring in the liver. Although SBRT can be highly effective for establishing local control in hepatic malignancies, a tradeoff exists between tumor control and normal tissue complications. The objective of the present study was to review the normal tissue dose-volume effects for SBRT-induced liver and gastrointestinal toxicities and derive normal tissue complication probability models. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Local Control After Stereotactic Body Radiation Therapy for Liver Tumors.
- Author
-
Ohri, Nitin, Tomé, Wolfgang A., Méndez Romero, Alejandra, Miften, Moyed, Ten Haken, Randall K., Dawson, Laura A., Grimm, Jimm, Yorke, Ellen, and Jackson, Andrew
- Subjects
- *
LIVER tumors , *RADIOTHERAPY , *LIVER metastasis , *SURVIVAL analysis (Biometry) , *LOG-rank test - Abstract
Purpose: To quantitatively evaluate published experiences with hepatic stereotactic body radiation therapy (SBRT), to determine local control rates after treatment of primary and metastatic liver tumors and to examine whether outcomes are affected by SBRT dosing regimen.Methods and Materials: We identified published articles that reported local control rates after SBRT for primary or metastatic liver tumors. Biologically effective doses (BEDs) were calculated for each dosing regimen using the linear-quadratic equation. We excluded series in which a wide range of BEDs was used. Individual lesion data for local control were extracted from actuarial survival curves, and data were aggregated to form a single dataset. Actuarial local control curves were generated using the Kaplan-Meier method after grouping lesions by disease type and BED (<100 Gy10 vs >100 Gy10). Comparisons were made using log-rank testing.Results: Thirteen articles met all inclusion criteria and formed the dataset for this analysis. The 1-, 2-, and 3-year actuarial local control rates after SBRT for primary liver tumors (n = 431) were 93%, 89%, and 86%, respectively. Lower 1- (90%), 2- (79%), and 3-year (76%) actuarial local control rates were observed for liver metastases (n = 290, log-rank P = .011). Among patients treated with SBRT for primary liver tumors, there was no evidence that local control is influenced by BED within the range of schedules used. For liver metastases, on the other hand, outcomes were significantly better for lesions treated with BEDs exceeding 100 Gy10 (3-year local control 93%) than for those treated with BEDs of ≤100 Gy10 (3-year local control 65%, P < .001).Conclusions: Stereotactic body radiation therapy for primary liver tumors provides high rates of durable local control, with no clear evidence for a dose-response relationship among commonly utilized schedules. Excellent local control rates are also seen after SBRT for liver metastases when BEDs of >100 Gy10 are utilized. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
36. A Phase 2 Study of Post-Operative Stereotactic Body Radiation Therapy (SBRT) for Solid Tumor Spine Metastases.
- Author
-
Redmond, Kristin J., Sciubba, Daniel, Khan, Majid, Gui, Chengcheng, Lo, Sheng-fu Larry, Gokaslan, Ziya L., Leaf, Brianne, Kleinberg, Lawrence, Grimm, Jimm, Ye, Xiaobu, and Lim, Michael
- Subjects
- *
METASTASIS , *KARNOFSKY Performance Status , *RADIOTHERAPY , *MAGNETIC resonance imaging , *SPINAL cord , *DISEASE progression , *RESEARCH , *PAIN measurement , *TIME , *RESEARCH methodology , *CANCER relapse , *RADIATION , *EVALUATION research , *MEDICAL cooperation , *TREATMENT effectiveness , *COMPARATIVE studies , *POSTOPERATIVE period , *RADIOSURGERY , *SPINAL tumors , *LONGITUDINAL method , *NEUROLOGIC examination - Abstract
Purpose: In patients with spinal instability, cord compression, or neurologic deficits, the standard of care is surgery followed by radiation therapy (RT). Recurrence rates after conventional RT remain high. The purpose of this study is to prospectively examine the efficacy of postoperative stereotactic body RT (SBRT) in patients who have undergone surgical intervention for spine metastases. We hypothesize that postoperative SBRT to the spine would be associated with higher local control than historical rates after conventional RT.Methods and Materials: Thirty-five adult patients with a Karnofsky Performance Status score ≥40 and spine metastases from solid tumors with no prior overlapping RT and target volumes ≤3 consecutive vertebral levels were enrolled. Thirty-three patients were treated. Two patients underwent treatment to 2 target volumes for a total of 35 target volumes. All patients received SBRT 30 Gy in 5 fractions. Patients were followed with neurological examinations and computed tomography and/or magnetic resonance imaging every 3 months. Neurologic function was assessed at the same time points using the American Spinal Injury Association (ASIA) impairment score. Pain was rated according to the 10-point visual analogue scale and MD Anderson Cancer Center brief pain index. Toxicity was recorded according to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4. The primary objective was the rate of radiographic local recurrence at 12 months after completion of SBRT.Results: Patient characteristics were as follows: 34.3% had radioresistant primaries; 71.4% were ASIA E and the remainder ASIA D; and the median baseline Karnofsky Performance Status score was 70 (range, 50-100). Radiographic and symptomatic local control at 1 year were 90% (95% confidence interval, 76%-98%). The median time to recurrence in these 3 patients was 3.5 months (range, 3.4-5.8 months), all had radiosensitive tumors, and all recurrences were epidural. No patients experienced wound dehiscence, hardware failure, or spinal cord myelopathy. The median time to return to systemic therapy was 0.5 months (range, 0-9.4 months).Conclusions: This prospective study of postoperative spine SBRT demonstrates excellent local control with low toxicity. These data suggest superior rates of local control compared with conventional RT; however, a formal comparative study is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
37. In Reply to Schultheiss.
- Author
-
Moiseenko, Vitali, Hattangadi-Gluth, Jona A., Huynh-Le, Minh-Phuong, Marks, Lawrence B., Grimm, Jimm, Milano, Michael T., Jackson, Andrew, Yorke, Ellen, Pettersson, Niclas, and Naqa, Issam El
- Published
- 2021
- Full Text
- View/download PDF
38. In Regard to Soltys et al.
- Author
-
Chowdhry, Amit K., Milano, Michael T., Soltys, Scott G., and Grimm, Jimm
- Published
- 2021
- Full Text
- View/download PDF
39. Distinguishing True Progression From Radionecrosis After Stereotactic Radiation Therapy for Brain Metastases With Machine Learning and Radiomics.
- Author
-
Peng, Luke, Parekh, Vishwa, Huang, Peng, Lin, Doris D., Sheikh, Khadija, Baker, Brock, Kirschbaum, Talia, Silvestri, Francesca, Son, Jessica, Robinson, Adam, Huang, Ellen, Ames, Heather, Grimm, Jimm, Chen, Linda, Shen, Colette, Soike, Michael, McTyre, Emory, Redmond, Kristin, Lim, Michael, and Lee, Junghoon
- Subjects
- *
RADIOTHERAPY , *BRAIN metastasis , *MACHINE learning , *MAGNETIC resonance imaging , *COHORT analysis - Abstract
Purpose: Treatment effect or radiation necrosis after stereotactic radiosurgery (SRS) for brain metastases is a common phenomenon often indistinguishable from true progression. Radiomics is an emerging field that promises to improve on conventional imaging. In this study, we sought to apply a radiomics-based prediction model to the problem of diagnosing treatment effect after SRS.Methods and Materials: We included patients in the Johns Hopkins Health System who were treated with SRS for brain metastases who subsequently underwent resection for symptomatic growth. We also included cases of likely treatment effect in which lesions grew but subsequently regressed spontaneously. Lesions were segmented semiautomatically on preoperative T1 postcontrast and T2 fluid-attenuated inversion recovery magnetic resonance imaging, and radiomic features were extracted with software developed in-house. Top-performing features on univariate logistic regression were entered into a hybrid feature selection/classification model, IsoSVM, with parameter optimization and further feature selection performed using leave-one-out cross-validation. Final model performance was assessed by 10-fold cross-validation with 100 repeats. All cases were independently reviewed by a board-certified neuroradiologist for comparison.Results: We identified 82 treated lesions across 66 patients, with 77 lesions having pathologic confirmation. There were 51 radiomic features extracted per segmented lesion on each magnetic resonance imaging sequence. An optimized IsoSVM classifier based on top-ranked radiomic features had sensitivity and specificity of 65.38% and 86.67%, respectively, with an area under the curve of 0.81 on leave-one-out cross-validation. Only 73% of cases were classifiable by the neuroradiologist, with a sensitivity of 97% and specificity of 19%.Conclusions: Radiomics holds promise for differentiating between treatment effect and true progression in brain metastases treated with SRS. A predictive model built on radiomic features from an institutional cohort performed well on cross-validation testing. These results warrant further validation in independent datasets. Such work could prove invaluable for guiding management of individual patients and assessing outcomes of novel interventions. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
40. Radiation-Induced Edema After Single-Fraction or Multifraction Stereotactic Radiosurgery for Meningioma: A Critical Review.
- Author
-
Milano, Michael T., Sharma, Manju, Soltys, Scott G., Sahgal, Arjun, Usuki, Kenneth Y., Saenz, Jon-Michael, Grimm, Jimm, and El Naqa, Issam
- Subjects
- *
STEREOTACTIC radiosurgery , *MENINGIOMA , *EDEMA , *CANCER radiotherapy complications , *MEDICAL dosimetry , *DRUG dosage , *THERAPEUTICS , *CANCER radiotherapy , *CANCER , *CEREBRAL edema , *MENINGES , *RADIATION doses , *RADIOSURGERY , *TIME , *SYSTEMATIC reviews - Abstract
Purpose: Potential dosimetric and clinicopathologic predictors of radiation-induced brain edema after single-fraction or multifraction stereotactic radiosurgery (SRS) for non-base of skull (non-BOS) meningiomas are summarized based on a systematic review of the published literature.Methods and Materials: Reviewed studies (PubMed indexed from 1998 through 2017) included all or some non-BOS meningioma patients, reported risks of edema after SRS, and correlated dosimetric and/or nondosimetric measures with the magnitude of risk.Results: Twenty-six studies reporting risks of edema after SRS for meningioma are reviewed. The treatment techniques as well as distribution of tumor locations, target dosing, and target volume varied across studies. Among 13 studies that included only non-BOS tumors or separately grouped non-BOS tumors, symptomatic edema occurred in 5% to 43% of patients and any edema occurred in 28% to 50%. The reported average time to onset of edema ranged from approximately 3 to 9 months in most studies. Factors reported to significantly correlate with increased risks of edema and/or symptomatic edema after SRS for meningioma include the following: greater tumor margin and/or maximum dose, greater tumor size and/or volume, non-BOS (particularly parasagittal) location, no prior resection for meningioma, and presence of pretreatment edema. Nevertheless, the extent and significance of these factors were inconsistent across studies. Potentially important dosimetric factors, such as volume of brain or tissue receiving single-fraction doses > 10 to 12 Gy, are not well studied.Conclusions: The variability in risks of edema and in factors impacting those risks is likely a result of differences across studies in the clinicopathologic characteristics of the patient populations, as well as differences in treatment modalities and SRS planning and delivery parameters. More studies on pooled populations, grouped by potential prognostic factors such as tumor location and prior therapy, are needed to better understand dosimetric and nondosimetric factors predictive of edema risk after SRS for meningioma. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
41. Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.
- Author
-
Zhao, Jing, Yorke, Ellen D., Li, Ling, Kavanagh, Brian D., Li, X. Allen, Das, Shiva, Miften, Moyed, Rimner, Andreas, Campbell, Jeffrey, Xue, Jinyu, Jackson, Andrew, Grimm, Jimm, Milano, Michael T., and (Spring) Kong, Feng-Ming
- Subjects
- *
CANCER treatment , *SMALL cell lung cancer , *RADIOTHERAPY , *RADIATION dosimetry , *DATA analysis , *STATISTICAL correlation ,RISK factors - Abstract
Purpose: To study the risk factors for radiation-induced lung toxicity (RILT) after stereotactic body radiation therapy (SBRT) of the thorax.Methods and Materials: Published studies on lung toxicity in patients with early-stage non-small cell lung cancer (NSCLC) or metastatic lung tumors treated with SBRT were pooled and analyzed. The primary endpoint was RILT, including pneumonitis and fibrosis. Data of RILT and risk factors were extracted from each study, and rates of grade 2 to 5 (G2+) and grade 3 to 5 (G3+) RILT were computed. Patient, tumor, and dosimetric factors were analyzed for their correlation with RILT.Results: Eighty-eight studies (7752 patients) that reported RILT incidence were eligible. The pooled rates of G2+ and G3+ RILT from all 88 studies were 9.1% (95% confidence interval [CI]: 7.15-11.4) and 1.8% (95% CI: 1.3-2.5), respectively. The median of median tumor sizes was 2.3 (range, 1.4-4.1) cm. Among the factors analyzed, older patient age (P=.044) and larger tumor size (the greatest diameter) were significantly correlated with higher rates of G2+ (P=.049) and G3+ RILT (P=.001). Patients with stage IA versus stage IB NSCLC had significantly lower risks of G2+ RILT (8.3% vs 17.1%, odds ratio = 0.43, 95% CI: 0.29-0.64, P<.0001). Among studies that provided detailed dosimetric data, the pooled analysis demonstrated a significantly higher mean lung dose (MLD) (P=.027) and V20 (P=.019) in patients with G2+ RILT than in those with grade 0 to 1 RILT.Conclusions: The overall rate of RILT is relatively low after thoracic SBRT. Older age and larger tumor size are significant adverse risk factors for RILT. Lung dosimetry, specifically lung V20 and MLD, also significantly affect RILT risk. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
42. In Reply to Klement et al.
- Author
-
Ohri, Nitin, Tomé, Wolfgang A., Romero, Alejandra Méndez, Miften, Moyed, Ten Haken, Randall K., Dawson, Laura, Grimm, Jimm, Yorke, Ellen, and Jackson, Andrew
- Published
- 2021
- Full Text
- View/download PDF
43. In Reply to Tsurugai et al.
- Author
-
Ohri, Nitin, Tomé, Wolfgang A., Romero, Alejandra Méndez, Miften, Moyed, Haken, Randall K. Ten, Dawson, Laura A., Grimm, Jimm, Yorke, Ellen, and Jackson, Andrew
- Published
- 2022
- Full Text
- View/download PDF
44. Anatomy-Based Inverse Planning Simulated Annealing Optimization in High-Dose-Rate Prostate Brachytherapy: Significant Dosimetric Advantage Over Other Optimization Techniques
- Author
-
Jacob, Dayee, Raben, Adam, Sarkar, Abhirup, Grimm, Jimm, and Simpson, Larry
- Subjects
- *
RADIOISOTOPE brachytherapy , *MATHEMATICAL optimization , *CANCER treatment , *RADIOTHERAPY - Abstract
Purpose: To perform an independent validation of an anatomy-based inverse planning simulated annealing (IPSA) algorithm in obtaining superior target coverage and reducing the dose to the organs at risk. Method and Materials: In a recent prostate high-dose-rate brachytherapy protocol study by the Radiation Therapy Oncology Group (0321), our institution treated 20 patients between June 1, 2005 and November 30, 2006. These patients had received a high-dose-rate boost dose of 19 Gy to the prostate, in addition to an external beam radiotherapy dose of 45 Gy with intensity-modulated radiotherapy. Three-dimensional dosimetry was obtained for the following optimization schemes in the Plato Brachytherapy Planning System, version 14.3.2, using the same dose constraints for all the patients treated during this period: anatomy-based IPSA optimization, geometric optimization, and dose point optimization. Dose–volume histograms were generated for the planning target volume and organs at risk for each optimization method, from which the volume receiving at least 75% of the dose (V75%) for the rectum and bladder, volume receiving at least 125% of the dose (V125%) for the urethra, and total volume receiving the reference dose (V100%) and volume receiving 150% of the dose (V150%) for the planning target volume were determined. The dose homogeneity index and conformal index for the planning target volume for each optimization technique were compared. Results: Despite suboptimal needle position in some implants, the IPSA algorithm was able to comply with the tight Radiation Therapy Oncology Group dose constraints for 90% of the patients in this study. In contrast, the compliance was only 30% for dose point optimization and only 5% for geometric optimization. Conclusions: Anatomy-based IPSA optimization proved to be the superior technique and also the fastest for reducing the dose to the organs at risk without compromising the target coverage. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
45. In Reply to Klement et al.
- Author
-
Ohri, Nitin, Tomé, Wolfgang A, Romero, Alejandra Méndez, Miften, Moyed, Ten Haken, Randall K, Dawson, Laura, Grimm, Jimm, Yorke, Ellen, and Jackson, Andrew
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.